Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4921 AL 4935

A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes

Alam Q, ZubairAlam M, Karim S, Gan SH, Kamal MA, Jiman-Fatani A, Damanhouri GA, Abuzenadah AM, Chaudhary AG, Haque A.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):478-86. doi: 10.2174/18715273113126660159.

Bacteriophage--a common divergent therapeutic approach for Alzheimer's disease and type II diabetes mellitus

Sohrab SS, Karim S, Kamal MA, Abuzenadah AM, Chaudhary AG, Al-Qahtani MH, Mirza Z.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):491-500. doi: 10.2174/18715273113126660158.

Alzheimer's and type 2 diabetes treatment via common enzyme targeting

Jabir NR, Kamal MA, Abuzenadah AM, Gan SH, Alama MN, Baeesa SS, Tabrez S.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):299-304. doi: 10.2174/18715273113126660145.

The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications

Zemva J, Schubert M.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):322-37. doi: 10.2174/18715273113126660141.

Fighting Alzheimer's disease and type 2 diabetes: pathological links and treatment strategies

Dai Y, Kamal MA.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):271-82. doi: 10.2174/18715273113126660134.

Anesthetics and its impact on the brain and Alzheimer's disease

Mandal PK, Ritchie K, Fodale V.

J Alzheimers Dis. 2014;39(2):223-5. doi: 10.3233/JAD-131487.

The effects of different antioxidants on the activity of cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer's disease and age-matched normal brains

Kairane C, Mahlapuu R, Ehrlich K, Zilmer M, Soomets U.

Curr Alzheimer Res. 2014 Jan;11(1):79-85. doi: 10.2174/15672050113106660179.

Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease

Rodrigues Simões MC, Dias Viegas FP, Moreira MS, de Freitas Silva M, Riquiel MM, da Rosa PM, Castelli MR, dos Santos MH, Soares MG, Viegas C Jr.

Mini Rev Med Chem. 2014 Jan;14(1):2-19. doi: 10.2174/1389557513666131119201353.

A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease

Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP.

Curr Alzheimer Res. 2014 Jan;11(1):47-58. doi: 10.2174/1567205010666131212110148.

Systematic review of the effects of exercise on activities of daily living in people with Alzheimer's disease

Rao AK, Chou A, Bursley B, Smulofsky J, Jezequel J.

Am J Occup Ther. 2014 Jan-Feb;68(1):50-6. doi: 10.5014/ajot.2014.009035.

Vitamin E, memantine, and Alzheimer disease

Evans DA, Morris MC, Rajan KB.

JAMA. 2014 Jan 1;311(1):29-30. doi: 10.1001/jama.2013.282835.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD.

JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834.

Emerging therapeutics for Alzheimer's disease

Chiang K, Koo EH.

Annu Rev Pharmacol Toxicol. 2014;54:381-405. doi: 10.1146/annurev-pharmtox-011613-135932.

Omega-3 fatty acids: a growing ocean of choices

Fares H, Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV.

Curr Atheroscler Rep. 2014 Feb;16(2):389. doi: 10.1007/s11883-013-0389-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias